A distinct p53 target gene set predicts for response to the selective p53–HDM2 inhibitor NVP-CGM097

Abstract 4638: NVP-CGM097: a novel p53-Mdm2 inhibitor exhibiting potent antitumor activity in mouse models of human cancer

(2015) Stéphane Ferretti et al.   CANCER RESEARCH

Abstract 1797: Discovery of NVP-CGM097, a highly potent and optimized small molecule inhibitor of Mdm2 under evaluation in a Phase I clinical trial

(2015) Sebastien Jeay et al.   CANCER RESEARCH

Global analysis of p53-regulated transcription identifies its direct targets and unexpected regulatory mechanisms

(2014) Mary Ann Allen et al.   eLife

Control of Hematopoietic Stem Cell Emergence by Antagonistic Functions of Ribosomal Protein Paralogs

(2013) Yong Zhang et al.   DEVELOPMENTAL CELL

The central valine concept provides an entry in a new class of non peptide inhibitors of the p53–MDM2 interaction

(2012) Pascal Furet et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

(2012) Jordi Barretina et al.   NATURE

Translating p53 into the clinic

(2010) Chit Fang Cheok et al.   Nature Reviews Clinical Oncology

Ribosomal protein S27-like and S27 interplay with p53-MDM2 axis as a target, a substrate and a regulator

(2010) X Xiong et al.   ONCOGENE

The p53 orchestra: Mdm2 and Mdmx set the tone

(2010) Mark Wade et al.   TRENDS IN CELL BIOLOGY

Blinded by the Light: The Growing Complexity of p53

(2009) Karen H. Vousden et al.   CELL

Mdm2-mediated ubiquitylation: p53 and beyond

(2009) J-C Marine et al.   CELL DEATH AND DIFFERENTIATION

p53 target gene AEN is a nuclear exonuclease required for p53-dependent apoptosis

(2008) T Kawase et al.   ONCOGENE